K. OGASAWARA

9.6k total citations · 1 hit paper
195 papers, 4.9k citations indexed

About

K. OGASAWARA is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, K. OGASAWARA has authored 195 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Oncology, 42 papers in Immunology and 30 papers in Molecular Biology. Recurrent topics in K. OGASAWARA's work include CAR-T cell therapy research (26 papers), Immune Cell Function and Interaction (20 papers) and T-cell and B-cell Immunology (18 papers). K. OGASAWARA is often cited by papers focused on CAR-T cell therapy research (26 papers), Immune Cell Function and Interaction (20 papers) and T-cell and B-cell Immunology (18 papers). K. OGASAWARA collaborates with scholars based in Japan, United States and Germany. K. OGASAWARA's co-authors include Tadanori Aizawa, Wataru Hashimoto, Katsuo Kumagai, Junichi Taguchi, Shuji Seki, R. A. Good, Hisashi Arase, Hideaki Kaneda, Minoru Ohno and Tomohiro Terada and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Circulation and Journal of Clinical Oncology.

In The Last Decade

K. OGASAWARA

180 papers receiving 4.8k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study

2022 186 citations Jeremy S. Abramson, Scott R. Solomon et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
K. OGASAWARA Japan	39	1.6k	1.5k	950	576	502	195	4.9k
Giuseppe Grandaliano Italy	46	1.4k 0.9×	1.0k 0.7×	1.6k 1.6×	1.4k 2.5×	303 0.6×	222	6.9k
Susanne Osanto Netherlands	37	761 0.5×	1.4k 0.9×	1.9k 2.0×	531 0.9×	738 1.5×	95	5.1k
Kevin Horgan United States	34	2.3k 1.4×	951 0.6×	1.0k 1.1×	3.2k 5.5×	533 1.1×	63	9.1k
Shinichi Kawai Japan	42	1.3k 0.8×	914 0.6×	1.1k 1.2×	424 0.7×	166 0.3×	181	6.4k
Giovanni Stallone Italy	40	886 0.5×	1.3k 0.8×	1.2k 1.2×	1.3k 2.2×	132 0.3×	179	5.6k
Joe‐Elie Salem France	39	552 0.3×	2.3k 1.5×	1.0k 1.1×	615 1.1×	1.8k 3.7×	181	5.7k
Richard D. Hockett United States	25	1.1k 0.7×	588 0.4×	927 1.0×	1.0k 1.7×	2.0k 4.0×	47	4.9k
Paul A.M. van Leeuwen Netherlands	48	1.0k 0.6×	1.8k 1.2×	843 0.9×	1.5k 2.7×	871 1.7×	194	7.1k
Francesco Paolo D’Armiento Italy	35	753 0.5×	581 0.4×	949 1.0×	1.4k 2.5×	599 1.2×	128	4.8k
Patrick D. Walker United States	42	514 0.3×	498 0.3×	1.4k 1.5×	538 0.9×	164 0.3×	122	5.1k

Countries citing papers authored by K. OGASAWARA

Since Specialization

Citations

This map shows the geographic impact of K. OGASAWARA's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. OGASAWARA with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. OGASAWARA more than expected).

Fields of papers citing papers by K. OGASAWARA

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. OGASAWARA. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. OGASAWARA. The network helps show where K. OGASAWARA may publish in the future.

Co-authorship network of co-authors of K. OGASAWARA

This figure shows the co-authorship network connecting the top 25 collaborators of K. OGASAWARA. A scholar is included among the top collaborators of K. OGASAWARA based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. OGASAWARA. K. OGASAWARA is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hu, Hongxiang, Yan Li, Julia Piasecki, et al.. (2025). Population Pharmacokinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-cell Product, in Patients with Relapsed/Refractory Multiple Myeloma. Clinical Cancer Research. 31(6). 1163–1171. 3 indexed citations

Chang, Ming, Yizhe Chen, K. OGASAWARA, Brian J. Schmidt, & Lu Gaohua. (2024). Advancements in physiologically based pharmacokinetic modeling for fedratinib: updating dose guidance in the presence of a dual inhibitor of CYP3A4 and CYP2C19. Cancer Chemotherapy and Pharmacology. 94(4). 549–559.

Hu, Hongxiang, et al.. (2024). Population Cellular Kinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Multiple Myeloma. 1 indexed citations

Abramson, Jeremy S., Scott R. Solomon, Jon Arnason, et al.. (2024). Plain language summary of the TRANSFORM study primary analysis results: liso-cell as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen. Future Oncology. 20(21). 1455–1465. 1 indexed citations

Palomba, M. Lia, Tanya Siddiqi, Leo I. Gordon, et al.. (2024). Lisocabtagene Maraleucel (liso-cel) in Patients (Pt) with R/R MCL: Subgroup Analyses in Pts with High-Risk Disease Features from the MCL Cohort of the TRANSCEND NHL 001. Transplantation and Cellular Therapy. 30(2). S14–S14. 2 indexed citations

Gokemeijer, Jochem, K. OGASAWARA, Vijay Upreti, et al.. (2023). An IQ Consortium Perspective on Best Practices for Bioanalytical and Immunogenicity Assessment Aspects of CAR‐T and TCR‐T Cellular Therapies Development. Clinical Pharmacology & Therapeutics. 115(2). 188–200. 2 indexed citations

Solomon, Scott R., Amitkumar Mehta, Jeremy S. Abramson, et al.. (2021). Experience of Prior Anti-CD19 Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Non-Hodgkin Lymphoma (B-NHL) Receiving Lisocabtagene Maraleucel (liso-cel), an Investigational Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Product. Transplantation and Cellular Therapy. 27(3). S207–S208. 3 indexed citations

OGASAWARA, K., et al.. (2020). Excretion balance and pharmacokinetics following a single oral dose of [14C]-fedratinib in healthy subjects. Cancer Chemotherapy and Pharmacology. 86(2). 307–314. 11 indexed citations

OGASAWARA, K., Shripad Chitnis, Reginald Gohh, Uwe Christians, & Fatemeh Akhlaghi. (2013). Multidrug Resistance-Associated Protein 2 (MRP2/ABCC2) Haplotypes Significantly Affect the Pharmacokinetics of Tacrolimus in Kidney Transplant Recipients. Clinical Pharmacokinetics. 52(9). 751–762. 70 indexed citations

10.

Aoki, Masayo, Tomohiro Terada, K. OGASAWARA, et al.. (2009). Impact of regulatory polymorphisms in organic anion transporter genes in the human liver. Pharmacogenetics and Genomics. 19(8). 647–656. 18 indexed citations

11.

Fujimoto, Hajime, Hisae Kobayashi, K. OGASAWARA, Minoru Yamakado, & Minoru Ohno. (2009). Association of the manganese superoxide dismutase polymorphism with vasospastic angina pectoris. Journal of Cardiology. 55(2). 205–210. 16 indexed citations

12.

Matsuno, Shunsuke, Junji Yajima, Yuji Oikawa, et al.. (2009). Application of pressure wire for functional evaluation of angiographically inapparent external iliac artery stenosis: A case report. 24(3). 237–241. 1 indexed citations

13.

OGASAWARA, K., Tomohiro Terada, Hideyuki Motohashi, et al.. (2008). Analysis of regulatory polymorphisms in organic ion transporter genes (SLC22A) in the kidney. Journal of Human Genetics. 53(7). 607–614. 33 indexed citations

14.

Oikawa, Yuji, Junji Yajima, Ryuichi Funada, et al.. (2008). PJ-142 Angioscopic and Histopathological Characterization of Heterogeneous Patterns of Restenosis After Sirolimus-Eluting Stent Implantation : Insights into Potential "Thromborestenosis" Phenomenon(Intravascular endoscopy/Intravascular ultrasound(05)(I),Poster Session(Japanese),The 72nd Annual Scientific Meeting of the Japanese Circulation Society). Japanese Circulation Journal-english Edition. 72. 546–547. 1 indexed citations

15.

Yamashita, Takeshi, Shinya Suzuki, Koichi Sagara, et al.. (2008). 1 Lessons from a Prospective Cohort Study of Shinken Database 2004-5 : Mortality and Morbidity of Japanese AF Patients under Standard Management(Symposium 6 (SY-06) (A) Recent Strategies for Total Management of Atrial Fibrillation,Special Program,The 72nd Annual Scientific Meeting of the Japanese Circulation Society). Japanese Circulation Journal-english Edition. 72. 35. 3 indexed citations

16.

Kawaji, Shigeyasu, et al.. (2002). Rhythm-based control of biped locomotion robot. 93–98. 2 indexed citations

17.

Tajima, Akihiko, Akira Koike, K. OGASAWARA, et al.. (2002). [Prevalence and clinical background of exercise-induced ventricular tachycardia during exercise testing].. PubMed. 39(4). 205–12. 1 indexed citations

18.

Iwabuchi, Chikako, Kazuhisa Iwabuchi, T Takayanagi, et al.. (1998). Intrathymic selection of NK1.1+((( T cell antigen receptor (TCR)+ cells in transgenic mice bearing TCR specific for chicken ovalbumin and restricted to I-Ad.. 21. 247–252. 1 indexed citations

19.

Seki, Shinichiro, Wataru Hashimoto, K. OGASAWARA, et al.. (1997). Antimetastatic effect of NK1⁺ T cells on experimental haematogenous tumour metastases in the liver and lungs of mice. Immunology. 92(4). 561–566. 52 indexed citations

20.

Kametani, Tetsuji, et al.. (1974). Studies on the syntheses of heterocyclic compounds—DXLV. Tetrahedron. 30(9). 1047–1051. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact